GeneHealth - Your precision medicine

Supravalvular Aortic Stenosis

Disease Details

Family Health Simplified

Buy Membership

Description: Supravalvular aortic stenosis is a congenital heart defect characterized by the narrowing of the ascending aorta above the aortic valve, leading to restricted blood flow from the heart.
Type: Supravalvular aortic stenosis is typically an autosomal dominant disorder.
Signs And Symptoms: Signs and symptoms of supravalvular aortic stenosis (SVAS) include:

- Heart murmur: Often the initial sign detected via stethoscope.
- Chest pain: Particularly during physical exertion.
- Shortness of breath: Especially noticeable during physical activities.
- Fatigue: Due to decreased cardiac output.
- Dizziness or fainting: Caused by reduced blood flow.
- Palpitations: Irregular or rapid heartbeats.
- Hypertension: Elevated blood pressure, particularly in the upper body.
- Poor growth or weight gain: Observed in infants and children.

Please note that SVAS may present differently based on the severity of the condition and the presence of other associated cardiovascular abnormalities.
Prognosis: Supravalvular aortic stenosis (SVAS) is a congenital narrowing of the aorta just above the aortic valve.

**Prognosis:**
The prognosis for SVAS varies depending on the severity of the stenosis and associated conditions. Mild cases may be asymptomatic and have a normal lifespan with regular monitoring. Moderate to severe cases often require surgical intervention to relieve the obstruction, improve symptoms, and prevent complications such as heart failure, arrhythmias, or sudden cardiac death. Post-surgical outcomes are generally good, although lifelong cardiac follow-up is necessary. Early diagnosis and appropriate management are crucial in improving overall prognosis.
Onset: Supravalvular aortic stenosis (SVAS) typically has a congenital onset, meaning it is present at birth. It can be associated with genetic conditions like Williams syndrome, or it may occur sporadically. Detection often happens in infancy or childhood during routine check-ups or when symptoms such as a heart murmur are noted.
Prevalence: The prevalence of supravalvular aortic stenosis (SVAS) is rare, estimated to occur in approximately 1 in 20,000 to 1 in 50,000 live births.
Epidemiology: Supravalvular aortic stenosis (SVAS) is a rare congenital cardiovascular disorder. It is characterized by the narrowing of the ascending aorta above the aortic valve. Epidemiologically, SVAS is often associated with Williams syndrome, a genetic condition caused by the deletion of genes on chromosome 7, including the elastin gene. The estimated prevalence of Williams syndrome is approximately 1 in 7,500 to 1 in 20,000 live births, and a significant proportion of these individuals exhibit SVAS. However, isolated cases of SVAS without Williams syndrome can also occur.
Intractability: Supravalvular aortic stenosis (SVAS) is a congenital heart defect characterized by narrowing above the aortic valve. The intractability of SVAS can vary depending on the severity of the condition. Mild cases may be managed with regular monitoring and medical management, while moderate to severe cases often require surgical intervention to relieve the stenosis. With appropriate treatment, many individuals can experience significant improvement, so it is not uniformly intractable. However, ongoing follow-up is typically necessary to monitor for potential complications.
Disease Severity: Supravalvular aortic stenosis (SVAS) is a heart condition characterized by the narrowing of the ascending aorta just above the aortic valve. The severity of SVAS can vary widely among individuals and can range from mild to severe. Mild cases may be asymptomatic and discovered incidentally, while severe cases can lead to significant obstruction of blood flow, causing symptoms such as chest pain, shortness of breath, fatigue, and even heart failure. The severity of the condition often dictates the need for medical management or surgical intervention.
Healthcare Professionals: Disease Ontology ID - DOID:1929
Pathophysiology: Supravalvular aortic stenosis (SVAS) is a congenital heart defect characterized by a narrowing of the ascending aorta just above the aortic valve. This narrowing can lead to an obstruction of blood flow from the left ventricle to the aorta, causing increased pressure in the left ventricle and subsequent hypertrophy of the heart muscle. The condition is often associated with Williams syndrome, a genetic disorder caused by a deletion on chromosome 7, which affects elastin production, an essential protein for the formation of blood vessels. Other complications can include coronary artery stenosis and aortic aneurysm. Hemodynamically, the obstruction increases afterload, affecting cardiac output and myocardial oxygen demand.
Carrier Status: Supravalvular aortic stenosis (SVAS) is generally caused by genetic mutations, most commonly in the ELN gene. It is typically inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the altered gene to be affected by the condition. Therefore, a carrier of the mutated gene will usually show symptoms, as carriers often present with the disease rather than being asymptomatic. Carrier status is not typically a concept applied to autosomal dominant conditions in the same way it is for autosomal recessive conditions.
Mechanism: Supravalvular aortic stenosis (SVAS) is a congenital condition characterized by the narrowing of the aorta just above the aortic valve. This narrowing obstructs blood flow from the heart to the rest of the body, leading to increased pressure in the left ventricle and potentially causing complications such as left ventricular hypertrophy, arrhythmias, or heart failure.

**Mechanism:**
In SVAS, the constriction occurs due to abnormal development of the aortic wall, often involving thickened and less elastic connective tissue. This structural abnormality impedes normal blood flow out of the heart, causing the left ventricle to work harder to pump blood through the narrowed segment of the aorta.

**Molecular Mechanisms:**
SVAS is frequently associated with genetic mutations, particularly those affecting the elastin gene (ELN). Elastin is a key protein that provides elasticity and strength to the vessel wall. Mutations in the ELN gene can lead to insufficient or dysfunctional elastin, resulting in the thick and non-compliant arterial walls seen in SVAS. This deficiency in elastin disrupts the normal architecture and function of the arterial wall, causing the stenotic phenotype observed in this condition. Inherited forms of SVAS, such as those seen in Williams-Beuren syndrome, are linked to deletions on chromosome 7 that include the ELN gene among other genes.
Treatment: Treatment of supravalvular aortic stenosis often involves surgical intervention to correct the narrowing of the aorta. The most common procedures include:

1. **Patch Aortoplasty:** A patch is sewn onto the aorta to widen the narrowed section.
2. **Bypass Grafting:** Blood flow is rerouted around the narrowed section using a graft.
3. **End-to-End Anastomosis:** The narrowed section is removed, and the two remaining ends are sewn together.

In some cases, medication may be prescribed to manage symptoms or associated conditions, but surgery is typically required to address the underlying stenosis. Regular monitoring and follow-up with a cardiologist are also important for ongoing management.
Compassionate Use Treatment: Supravalvular aortic stenosis (SVAS) is a rare congenital heart defect that can lead to severe cardiovascular complications if untreated. While there is no specific compassionate use treatment widely recognized for SVAS, management typically focuses on surgical intervention and symptomatic relief.

**Off-label or experimental treatments**:
1. **Sirolimus or Everolimus**: Although primarily used as immunosuppressants, these drugs have shown potential in experimental settings to treat vascular abnormalities due to their ability to inhibit the mTOR pathway, which affects cell proliferation and differentiation.

2. **Beta-blockers and Calcium Channel Blockers**: These medications are sometimes used off-label to manage symptoms and reduce cardiac workload by lowering blood pressure and heart rate.

3. **Endovascular Stenting**: In some experimental or compassionate use cases, stents have been used to relieve the stenosis and improve blood flow, although long-term efficacy and safety are still under study.

Treatment for SVAS should ideally be overseen by a specialist team familiar with the condition and the latest research developments.
Lifestyle Recommendations: For supravalvular aortic stenosis (SVAS), lifestyle recommendations often focus on managing symptoms and preventing complications:

1. **Activity Levels**: Engage in low to moderate-intensity physical activity, but avoid strenuous exercise or competitive sports that can strain the heart. Activities like walking, swimming, or cycling may be beneficial, but always consult a cardiologist for personalized advice.

2. **Regular Monitoring**: Have regular check-ups with a cardiologist to monitor the condition and adjust lifestyle recommendations as needed.

3. **Healthy Diet**: Maintain a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins. Limit intake of saturated fats, cholesterol, and sodium to manage blood pressure and overall heart health.

4. **Weight Management**: Keep a healthy weight to reduce the workload on the heart.

5. **Avoid Tobacco and Alcohol**: Refrain from smoking and limit alcohol consumption, as these can exacerbate cardiovascular issues.

6. **Stress Management**: Practice stress-reducing techniques such as yoga, meditation, or deep-breathing exercises to keep stress levels in check, which can be beneficial for heart health.

7. **Medication Adherence**: Take prescribed medications as directed by your healthcare provider to manage symptoms and prevent complications.

8. **Symptoms Awareness**: Be aware of symptoms such as chest pain, shortness of breath, dizziness, or fainting, and seek medical attention promptly if these occur.

Always follow specific recommendations and guidelines provided by your healthcare team.
Medication: Medication options for supravalvular aortic stenosis are generally limited, as this condition often requires surgical intervention. However, medication may be prescribed to manage symptoms or related conditions. These can include:

1. Beta-blockers or calcium channel blockers: To manage hypertension and reduce the heart's workload.
2. Diuretics: To reduce fluid retention and decrease the heart's overall workload.
3. ACE inhibitors or ARBs: To manage high blood pressure and reduce strain on the heart.

The primary treatment, especially in severe cases, is often surgery rather than medication alone.
Repurposable Drugs: No repurposable drugs are specifically approved for treating supravalvular aortic stenosis (SVAS). Treatment options primarily focus on surgical interventions to correct the narrowing of the aorta. Regular monitoring and management of associated conditions, such as hypertension, are important. Consult a cardiologist for personalized treatment recommendations.
Metabolites: Supravalvular aortic stenosis (SVAS) is a type of congenital heart defect where there is a narrowing above the aortic valve. The condition is not typically associated with specific metabolites. Instead, it is usually linked to genetic mutations, most commonly in the elastin gene (ELN). It's a structural abnormality rather than one associated with metabolic pathways.
Nutraceuticals: For supravalvular aortic stenosis, there aren't specific nutraceuticals recommended as a primary treatment. This condition is a congenital heart defect and typically requires medical or surgical intervention. Nutraceuticals might not have a significant impact on the structural abnormalities associated with this condition. Always consult a healthcare provider for appropriate management and treatment options.
Peptides: Supravalvular aortic stenosis is a congenital heart defect characterized by narrowing of the aorta just above the aortic valve. It is typically associated with genetic conditions such as Williams syndrome. Currently, there is limited information and research specifically targeting peptide-based therapies or nanoparticles (nan) for the treatment of supravalvular aortic stenosis. The standard treatment often involves surgical intervention to correct the narrowing and improve blood flow. Researchers are continually exploring new treatment methods, but as of now, peptide and nanoparticle therapies are not standard treatments for this condition.